Global Vaginitis Drug Market Insights, Forecast to 2031

TABLE OF CONTENTS

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Vaginitis Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
  • 1.2.2 External Drug
  • 1.2.3 Oral Drug
• 1.3 Market by Application
  • 1.3.1 Global Vaginitis Drug Market Share by Application: 2020 VS 2024 VS 2031
  • 1.3.2 Hospital Phamacy
  • 1.3.3 Retail Phamacy
  • 1.3.4 Online
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Vaginitis Drug Market Perspective (2020-2031)
• 2.2 Global Vaginitis Drug Growth Trends by Region
  • 2.2.1 Global Vaginitis Drug Market Size by Region: 2020 VS 2024 VS 2031
  • 2.2.2 Vaginitis Drug Market Size by Region (2020-2031)
• 2.3 Vaginitis Drug Market Dynamics
  • 2.3.1 Vaginitis Drug Industry Trends
  • 2.3.2 Vaginitis Drug Market Drivers
  • 2.3.3 Vaginitis Drug Market Challenges
  • 2.3.4 Vaginitis Drug Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Revenue Vaginitis Drug by Players
  • 3.1.1 Global Vaginitis Drug Revenue by Players (2020-2025)
  • 3.1.2 Global Vaginitis Drug Revenue Market Share by Players (2020-2025)
• 3.2 Global Vaginitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Global Key Players of Vaginitis Drug, Ranking by Revenue, 2023 VS 2024 VS 2025
• 3.4 Global Market Concentration Ratio
  • 3.4.1 Global Vaginitis Drug Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Vaginitis Drug Revenue in 2024
• 3.5 Global Key Players of Vaginitis Drug Head office and Area Served
• 3.6 Global Key Players of Vaginitis Drug, Product and Application
• 3.7 Global Key Players of Vaginitis Drug, Date of Enter into This Industry
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type

• 4.1 Global Vaginitis Drug Historic Market Size by Type (2020-2025)
• 4.2 Global Vaginitis Drug Forecasted Market Size by Type (2026-2031)

5 Breakdown Data by Application

• 5.1 Global Vaginitis Drug Historic Market Size by Application (2020-2025)
• 5.2 Global Vaginitis Drug Forecasted Market Size by Application (2026-2031)

6 North America

• 6.1 North America Vaginitis Drug Market Size (2020-2031)
• 6.2 North America Market Size by Type
  • 6.2.1 North America Vaginitis Drug Market Size by Type (2020-2031)
  • 6.2.2 North America Vaginitis Drug Market Share by Type (2020-2031)
• 6.3 North America Market Size by Application
  • 6.3.1 North America Vaginitis Drug Market Size by Application (2020-2031)
  • 6.3.2 North America Vaginitis Drug Market Share by Application (2020-2031)
• 6.4 North America Market Size by Country
  • 6.4.1 North America Vaginitis Drug Market Size by Country: 2020 VS 2024 VS 2031
  • 6.4.2 North America Vaginitis Drug Market Size by Country (2020-2031)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Vaginitis Drug Market Size (2020-2031)
• 7.2 Europe Market Size by Type
  • 7.2.1 Europe Vaginitis Drug Market Size by Type (2020-2031)
  • 7.2.2 Europe Vaginitis Drug Market Share by Type (2020-2031)
• 7.3 Europe Market Size by Application
  • 7.3.1 Europe Vaginitis Drug Market Size by Application (2020-2031)
  • 7.3.2 Europe Vaginitis Drug Market Share by Application (2020-2031)
• 7.4 Europe Market Size by Country
  • 7.4.1 Europe Vaginitis Drug Market Size by Country: 2020 VS 2024 VS 2031
  • 7.4.2 Europe Vaginitis Drug Market Size by Country (2020-2025)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 China

• 8.1 China Vaginitis Drug Market Size (2020-2031)
• 8.2 China Market Size by Type
  • 8.2.1 China Vaginitis Drug Market Size by Type (2020-2031)
  • 8.2.2 China Vaginitis Drug Market Share by Type (2020-2031)
• 8.3 China Market Size by Application
  • 8.3.1 China Vaginitis Drug Market Size by Application (2020-2031)
  • 8.3.2 China Vaginitis Drug Market Share by Application (2020-2031)

9 Asia (excluding China)

• 9.1 Asia Vaginitis Drug Market Size (2020-2031)
• 9.2 Asia Market Size by Type
  • 9.2.1 Asia Vaginitis Drug Market Size by Type (2020-2031)
  • 9.2.2 Asia Vaginitis Drug Market Share by Type (2020-2031)
• 9.3 Asia Market Size by Application
  • 9.3.1 Asia Vaginitis Drug Market Size by Application (2020-2031)
  • 9.3.2 Asia Vaginitis Drug Market Share by Application (2020-2031)
• 9.4 Asia Market Size by Region
  • 9.4.1 Asia Vaginitis Drug Market Size by Region: 2020 VS 2024 VS 2031
  • 9.4.2 Asia Vaginitis Drug Market Size by Region (2020-2031)
  • 9.4.3 Japan
  • 9.4.4 South Korea
  • 9.4.5 China Taiwan
  • 9.4.6 Southeast Asia
  • 9.4.7 India
  • 9.4.8 Australia

10 Middle East, Africa, and Latin America

• 10.1 Middle East, Africa, and Latin America Vaginitis Drug Market Size (2020-2031)
• 10.2 Middle East, Africa, and Latin America Market Size by Type
  • 10.2.1 Middle East, Africa, and Latin America Vaginitis Drug Market Size by Type (2020-2031)
  • 10.2.2 Middle East, Africa, and Latin America Vaginitis Drug Market Share by Type (2020-2031)
• 10.3 Middle East, Africa, and Latin America Market Size by Application
  • 10.3.1 Middle East, Africa, and Latin America Vaginitis Drug Market Size by Application (2020-2031)
  • 10.3.2 Middle East, Africa, and Latin America Market Share by Application (2020-2031)
• 10.4 Middle East, Africa, and Latin America Market Size by Country
  • 10.4.1 Middle East, Africa, and Latin America Vaginitis Drug Market Size by Country: 2020 VS 2024 VS 2031
  • 10.4.2 Middle East, Africa, and Latin America Vaginitis Drug Market Size by Country (2020-2031)
  • 10.4.3 Brazil
  • 10.4.4 Mexico
  • 10.4.5 Turkey
  • 10.4.6 Saudi Arabia
  • 10.4.7 Israel
  • 10.4.8 GCC Countries

11 Key Players Profiles

• 11.1 Pfizer
  • 11.1.1 Pfizer Company Details
  • 11.1.2 Pfizer Business Overview
  • 11.1.3 Pfizer Vaginitis Drug Introduction
  • 11.1.4 Pfizer Revenue in Vaginitis Drug Business (2020-2025)
  • 11.1.5 Pfizer Recent Development
• 11.2 Bayer
  • 11.2.1 Bayer Company Details
  • 11.2.2 Bayer Business Overview
  • 11.2.3 Bayer Vaginitis Drug Introduction
  • 11.2.4 Bayer Revenue in Vaginitis Drug Business (2020-2025)
  • 11.2.5 Bayer Recent Development
• 11.3 Sanofi
  • 11.3.1 Sanofi Company Details
  • 11.3.2 Sanofi Business Overview
  • 11.3.3 Sanofi Vaginitis Drug Introduction
  • 11.3.4 Sanofi Revenue in Vaginitis Drug Business (2020-2025)
  • 11.3.5 Sanofi Recent Development
• 11.4 Teva Pharmaceuticals
  • 11.4.1 Teva Pharmaceuticals Company Details
  • 11.4.2 Teva Pharmaceuticals Business Overview
  • 11.4.3 Teva Pharmaceuticals Vaginitis Drug Introduction
  • 11.4.4 Teva Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.4.5 Teva Pharmaceuticals Recent Development
• 11.5 Sandoz
  • 11.5.1 Sandoz Company Details
  • 11.5.2 Sandoz Business Overview
  • 11.5.3 Sandoz Vaginitis Drug Introduction
  • 11.5.4 Sandoz Revenue in Vaginitis Drug Business (2020-2025)
  • 11.5.5 Sandoz Recent Development
• 11.6 Prestige Consumer Healthcare
  • 11.6.1 Prestige Consumer Healthcare Company Details
  • 11.6.2 Prestige Consumer Healthcare Business Overview
  • 11.6.3 Prestige Consumer Healthcare Vaginitis Drug Introduction
  • 11.6.4 Prestige Consumer Healthcare Revenue in Vaginitis Drug Business (2020-2025)
  • 11.6.5 Prestige Consumer Healthcare Recent Development
• 11.7 Lupin Pharmaceuticals
  • 11.7.1 Lupin Pharmaceuticals Company Details
  • 11.7.2 Lupin Pharmaceuticals Business Overview
  • 11.7.3 Lupin Pharmaceuticals Vaginitis Drug Introduction
  • 11.7.4 Lupin Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.7.5 Lupin Pharmaceuticals Recent Development
• 11.8 Bausch Health
  • 11.8.1 Bausch Health Company Details
  • 11.8.2 Bausch Health Business Overview
  • 11.8.3 Bausch Health Vaginitis Drug Introduction
  • 11.8.4 Bausch Health Revenue in Vaginitis Drug Business (2020-2025)
  • 11.8.5 Bausch Health Recent Development
• 11.9 Globela Pharma
  • 11.9.1 Globela Pharma Company Details
  • 11.9.2 Globela Pharma Business Overview
  • 11.9.3 Globela Pharma Vaginitis Drug Introduction
  • 11.9.4 Globela Pharma Revenue in Vaginitis Drug Business (2020-2025)
  • 11.9.5 Globela Pharma Recent Development
• 11.10 Padagis
  • 11.10.1 Padagis Company Details
  • 11.10.2 Padagis Business Overview
  • 11.10.3 Padagis Vaginitis Drug Introduction
  • 11.10.4 Padagis Revenue in Vaginitis Drug Business (2020-2025)
  • 11.10.5 Padagis Recent Development
• 11.11 Galderma
  • 11.11.1 Galderma Company Details
  • 11.11.2 Galderma Business Overview
  • 11.11.3 Galderma Vaginitis Drug Introduction
  • 11.11.4 Galderma Revenue in Vaginitis Drug Business (2020-2025)
  • 11.11.5 Galderma Recent Development
• 11.12 Perrigo
  • 11.12.1 Perrigo Company Details
  • 11.12.2 Perrigo Business Overview
  • 11.12.3 Perrigo Vaginitis Drug Introduction
  • 11.12.4 Perrigo Revenue in Vaginitis Drug Business (2020-2025)
  • 11.12.5 Perrigo Recent Development
• 11.13 Johnson & Johnson
  • 11.13.1 Johnson & Johnson Company Details
  • 11.13.2 Johnson & Johnson Business Overview
  • 11.13.3 Johnson & Johnson Vaginitis Drug Introduction
  • 11.13.4 Johnson & Johnson Revenue in Vaginitis Drug Business (2020-2025)
  • 11.13.5 Johnson & Johnson Recent Development
• 11.14 Sinopharm Group
  • 11.14.1 Sinopharm Group Company Details
  • 11.14.2 Sinopharm Group Business Overview
  • 11.14.3 Sinopharm Group Vaginitis Drug Introduction
  • 11.14.4 Sinopharm Group Revenue in Vaginitis Drug Business (2020-2025)
  • 11.14.5 Sinopharm Group Recent Development
• 11.15 Tongfang Pharmaceuticals
  • 11.15.1 Tongfang Pharmaceuticals Company Details
  • 11.15.2 Tongfang Pharmaceuticals Business Overview
  • 11.15.3 Tongfang Pharmaceuticals Vaginitis Drug Introduction
  • 11.15.4 Tongfang Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.15.5 Tongfang Pharmaceuticals Recent Development
• 11.16 Lukang Pharmaceuticals
  • 11.16.1 Lukang Pharmaceuticals Company Details
  • 11.16.2 Lukang Pharmaceuticals Business Overview
  • 11.16.3 Lukang Pharmaceuticals Vaginitis Drug Introduction
  • 11.16.4 Lukang Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.16.5 Lukang Pharmaceuticals Recent Development
• 11.17 Kelun Pharmaceuticals
  • 11.17.1 Kelun Pharmaceuticals Company Details
  • 11.17.2 Kelun Pharmaceuticals Business Overview
  • 11.17.3 Kelun Pharmaceuticals Vaginitis Drug Introduction
  • 11.17.4 Kelun Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.17.5 Kelun Pharmaceuticals Recent Development
• 11.18 Shandong Shijiazhuang Pharmaceutical Group
  • 11.18.1 Shandong Shijiazhuang Pharmaceutical Group Company Details
  • 11.18.2 Shandong Shijiazhuang Pharmaceutical Group Business Overview
  • 11.18.3 Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Introduction
  • 11.18.4 Shandong Shijiazhuang Pharmaceutical Group Revenue in Vaginitis Drug Business (2020-2025)
  • 11.18.5 Shandong Shijiazhuang Pharmaceutical Group Recent Development
• 11.19 Livzon Pharmaceuticals
  • 11.19.1 Livzon Pharmaceuticals Company Details
  • 11.19.2 Livzon Pharmaceuticals Business Overview
  • 11.19.3 Livzon Pharmaceuticals Vaginitis Drug Introduction
  • 11.19.4 Livzon Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.19.5 Livzon Pharmaceuticals Recent Development
• 11.20 Wuhan Haite Biopharmaceuticals
  • 11.20.1 Wuhan Haite Biopharmaceuticals Company Details
  • 11.20.2 Wuhan Haite Biopharmaceuticals Business Overview
  • 11.20.3 Wuhan Haite Biopharmaceuticals Vaginitis Drug Introduction
  • 11.20.4 Wuhan Haite Biopharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.20.5 Wuhan Haite Biopharmaceuticals Recent Development
• 11.21 Dare Bioscience
  • 11.21.1 Dare Bioscience Company Details
  • 11.21.2 Dare Bioscience Business Overview
  • 11.21.3 Dare Bioscience Vaginitis Drug Introduction
  • 11.21.4 Dare Bioscience Revenue in Vaginitis Drug Business (2020-2025)
  • 11.21.5 Dare Bioscience Recent Development
• 11.22 Conba
  • 11.22.1 Conba Company Details
  • 11.22.2 Conba Business Overview
  • 11.22.3 Conba Vaginitis Drug Introduction
  • 11.22.4 Conba Revenue in Vaginitis Drug Business (2020-2025)
  • 11.22.5 Conba Recent Development
• 11.23 Luoxin Pharmaceuticals
  • 11.23.1 Luoxin Pharmaceuticals Company Details
  • 11.23.2 Luoxin Pharmaceuticals Business Overview
  • 11.23.3 Luoxin Pharmaceuticals Vaginitis Drug Introduction
  • 11.23.4 Luoxin Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.23.5 Luoxin Pharmaceuticals Recent Development
• 11.24 Yuanda Pharmaceuticals
  • 11.24.1 Yuanda Pharmaceuticals Company Details
  • 11.24.2 Yuanda Pharmaceuticals Business Overview
  • 11.24.3 Yuanda Pharmaceuticals Vaginitis Drug Introduction
  • 11.24.4 Yuanda Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.24.5 Yuanda Pharmaceuticals Recent Development
• 11.25 CR-Double Crane Pharmaceuticals
  • 11.25.1 CR-Double Crane Pharmaceuticals Company Details
  • 11.25.2 CR-Double Crane Pharmaceuticals Business Overview
  • 11.25.3 CR-Double Crane Pharmaceuticals Vaginitis Drug Introduction
  • 11.25.4 CR-Double Crane Pharmaceuticals Revenue in Vaginitis Drug Business (2020-2025)
  • 11.25.5 CR-Double Crane Pharmaceuticals Recent Development
• 11.26 HCPC
  • 11.26.1 HCPC Company Details
  • 11.26.2 HCPC Business Overview
  • 11.26.3 HCPC Vaginitis Drug Introduction
  • 11.26.4 HCPC Revenue in Vaginitis Drug Business (2020-2025)
  • 11.26.5 HCPC Recent Development
• 11.27 Yunnan Baiyao
  • 11.27.1 Yunnan Baiyao Company Details
  • 11.27.2 Yunnan Baiyao Business Overview
  • 11.27.3 Yunnan Baiyao Vaginitis Drug Introduction
  • 11.27.4 Yunnan Baiyao Revenue in Vaginitis Drug Business (2020-2025)
  • 11.27.5 Yunnan Baiyao Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
    • 13.1.1.1 Research Programs/Design
    • 13.1.1.2 Market Size Estimation
    • 13.1.1.3 Market Breakdown and Data Triangulation
  • 13.1.2 Data Source
    • 13.1.2.1 Secondary Sources
    • 13.1.2.2 Primary Sources
• 13.2 Author Details
• 13.3 Disclaimer

List of Tables

Table 1. Global Vaginitis Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of External Drug

Table 3. Key Players of Oral Drug

Table 4. Global Vaginitis Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Vaginitis Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Market Size by Region (2020-2031) & (US$ Million)

Table 7. Global Vaginitis Drug Market Share by Region (2020-2031)

Table 8. Market Trends

Table 9. Market Drivers

Table 10. Market Challenges

Table 11. Market Restraints

Table 12. Global Vaginitis Drug Revenue by Players (2020-2025) & (US$ Million)

Table 13. Global Vaginitis Drug Market Share by Players (2020-2025)

Table 14. Global Top Vaginitis Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaginitis Drug as of 2024)

Table 15. Global Vaginitis Drug Industry Ranking 2023 VS 2024

Table 16. Global 5 Largest Players Market Share by Vaginitis Drug Revenue (CR5 and HHI) & (2020-2025)

Table 17. Global Key Players of Vaginitis Drug, Headquarters and Area Served

Table 18. Global Key Players of Vaginitis Drug, Product and Application

Table 19. Global Key Players of Vaginitis Drug, Date of Enter into This Industry

Table 20. Mergers & Acquisitions, Expansion Plans

Table 21. Global Market Size by Type (2020-2025) & (US$ Million)

Table 22. Global Vaginitis Drug Revenue Market Share by Type (2020-2025)

Table 23. Global Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 24. Global Vaginitis Drug Revenue Market Share by Type (2026-2031)

Table 25. Global Market Size by Application (2020-2025) & (US$ Million)

Table 26. Global Vaginitis Drug Revenue Market Share by Application (2020-2025)

Table 27. Global Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 28. Global Vaginitis Drug Revenue Market Share by Application (2026-2031)

Table 29. North America Market Size by Type (2020-2031) & (US$ Million)

Table 30. North America Market Size by Application (2020-2031) & (US$ Million)

Table 31. North America Vaginitis Drug Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Market Size by Country (2020-2031) & (US$ Million)

Table 33. Europe Market Size by Type (2020-2031) & (US$ Million)

Table 34. Europe Market Size by Application (2020-2031) & (US$ Million)

Table 35. Europe Vaginitis Drug Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Market Size by Country (2020-2025) & (US$ Million)

Table 37. China Market Size by Type (2020-2031) & (US$ Million)

Table 38. China Market Size by Application (2020-2031) & (US$ Million)

Table 39. Asia Market Size by Type (2020-2031) & (US$ Million)

Table 40. Asia Market Size by Application (2020-2025) & (US$ Million)

Table 41. Asia Vaginitis Drug Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031

Table 42. Asia Market Size by Region (2020-2031) & (US$ Million)

Table 43. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million)

Table 44. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million)

Table 45. Middle East, Africa, and Latin America Vaginitis Drug Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million)

Table 47. Pfizer Company Details

Table 48. Pfizer Business Overview

Table 49. Pfizer Vaginitis Drug Product

Table 50. Pfizer Revenue (2020-2025) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Bayer Company Details

Table 53. Bayer Business Overview

Table 54. Bayer Vaginitis Drug Product

Table 55. Bayer Revenue (2020-2025) & (US$ Million)

Table 56. Bayer Recent Development

Table 57. Sanofi Company Details

Table 58. Sanofi Business Overview

Table 59. Sanofi Vaginitis Drug Product

Table 60. Sanofi Revenue (2020-2025) & (US$ Million)

Table 61. Sanofi Recent Development

Table 62. Teva Pharmaceuticals Company Details

Table 63. Teva Pharmaceuticals Business Overview

Table 64. Teva Pharmaceuticals Vaginitis Drug Product

Table 65. Teva Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 66. Teva Pharmaceuticals Recent Development

Table 67. Sandoz Company Details

Table 68. Sandoz Business Overview

Table 69. Sandoz Vaginitis Drug Product

Table 70. Sandoz Revenue (2020-2025) & (US$ Million)

Table 71. Sandoz Recent Development

Table 72. Prestige Consumer Healthcare Company Details

Table 73. Prestige Consumer Healthcare Business Overview

Table 74. Prestige Consumer Healthcare Vaginitis Drug Product

Table 75. Prestige Consumer Healthcare Revenue (2020-2025) & (US$ Million)

Table 76. Prestige Consumer Healthcare Recent Development

Table 77. Lupin Pharmaceuticals Company Details

Table 78. Lupin Pharmaceuticals Business Overview

Table 79. Lupin Pharmaceuticals Vaginitis Drug Product

Table 80. Lupin Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 81. Lupin Pharmaceuticals Recent Development

Table 82. Bausch Health Company Details

Table 83. Bausch Health Business Overview

Table 84. Bausch Health Vaginitis Drug Product

Table 85. Bausch Health Revenue (2020-2025) & (US$ Million)

Table 86. Bausch Health Recent Development

Table 87. Globela Pharma Company Details

Table 88. Globela Pharma Business Overview

Table 89. Globela Pharma Vaginitis Drug Product

Table 90. Globela Pharma Revenue (2020-2025) & (US$ Million)

Table 91. Globela Pharma Recent Development

Table 92. Padagis Company Details

Table 93. Padagis Business Overview

Table 94. Padagis Vaginitis Drug Product

Table 95. Padagis Revenue (2020-2025) & (US$ Million)

Table 96. Padagis Recent Development

Table 97. Galderma Company Details

Table 98. Galderma Business Overview

Table 99. Galderma Vaginitis Drug Product

Table 100. Galderma Revenue (2020-2025) & (US$ Million)

Table 101. Galderma Recent Development

Table 102. Perrigo Company Details

Table 103. Perrigo Business Overview

Table 104. Perrigo Vaginitis Drug Product

Table 105. Perrigo Revenue (2020-2025) & (US$ Million)

Table 106. Perrigo Recent Development

Table 107. Johnson & Johnson Company Details

Table 108. Johnson & Johnson Business Overview

Table 109. Johnson & Johnson Vaginitis Drug Product

Table 110. Johnson & Johnson Revenue (2020-2025) & (US$ Million)

Table 111. Johnson & Johnson Recent Development

Table 112. Sinopharm Group Company Details

Table 113. Sinopharm Group Business Overview

Table 114. Sinopharm Group Vaginitis Drug Product

Table 115. Sinopharm Group Revenue (2020-2025) & (US$ Million)

Table 116. Sinopharm Group Recent Development

Table 117. Tongfang Pharmaceuticals Company Details

Table 118. Tongfang Pharmaceuticals Business Overview

Table 119. Tongfang Pharmaceuticals Vaginitis Drug Product

Table 120. Tongfang Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 121. Tongfang Pharmaceuticals Recent Development

Table 122. Lukang Pharmaceuticals Company Details

Table 123. Lukang Pharmaceuticals Business Overview

Table 124. Lukang Pharmaceuticals Vaginitis Drug Product

Table 125. Lukang Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 126. Lukang Pharmaceuticals Recent Development

Table 127. Kelun Pharmaceuticals Company Details

Table 128. Kelun Pharmaceuticals Business Overview

Table 129. Kelun Pharmaceuticals Vaginitis Drug Product

Table 130. Kelun Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 131. Kelun Pharmaceuticals Recent Development

Table 132. Shandong Shijiazhuang Pharmaceutical Group Company Details

Table 133. Shandong Shijiazhuang Pharmaceutical Group Business Overview

Table 134. Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Product

Table 135. Shandong Shijiazhuang Pharmaceutical Group Revenue (2020-2025) & (US$ Million)

Table 136. Shandong Shijiazhuang Pharmaceutical Group Recent Development

Table 137. Livzon Pharmaceuticals Company Details

Table 138. Livzon Pharmaceuticals Business Overview

Table 139. Livzon Pharmaceuticals Vaginitis Drug Product

Table 140. Livzon Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 141. Livzon Pharmaceuticals Recent Development

Table 142. Wuhan Haite Biopharmaceuticals Company Details

Table 143. Wuhan Haite Biopharmaceuticals Business Overview

Table 144. Wuhan Haite Biopharmaceuticals Vaginitis Drug Product

Table 145. Wuhan Haite Biopharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 146. Wuhan Haite Biopharmaceuticals Recent Development

Table 147. Dare Bioscience Company Details

Table 148. Dare Bioscience Business Overview

Table 149. Dare Bioscience Vaginitis Drug Product

Table 150. Dare Bioscience Revenue (2020-2025) & (US$ Million)

Table 151. Dare Bioscience Recent Development

Table 152. Conba Company Details

Table 153. Conba Business Overview

Table 154. Conba Vaginitis Drug Product

Table 155. Conba Revenue (2020-2025) & (US$ Million)

Table 156. Conba Recent Development

Table 157. Luoxin Pharmaceuticals Company Details

Table 158. Luoxin Pharmaceuticals Business Overview

Table 159. Luoxin Pharmaceuticals Vaginitis Drug Product

Table 160. Luoxin Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 161. Luoxin Pharmaceuticals Recent Development

Table 162. Yuanda Pharmaceuticals Company Details

Table 163. Yuanda Pharmaceuticals Business Overview

Table 164. Yuanda Pharmaceuticals Vaginitis Drug Product

Table 165. Yuanda Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 166. Yuanda Pharmaceuticals Recent Development

Table 167. CR-Double Crane Pharmaceuticals Company Details

Table 168. CR-Double Crane Pharmaceuticals Business Overview

Table 169. CR-Double Crane Pharmaceuticals Vaginitis Drug Product

Table 170. CR-Double Crane Pharmaceuticals Revenue (2020-2025) & (US$ Million)

Table 171. CR-Double Crane Pharmaceuticals Recent Development

Table 172. HCPC Company Details

Table 173. HCPC Business Overview

Table 174. HCPC Vaginitis Drug Product

Table 175. HCPC Revenue (2020-2025) & (US$ Million)

Table 176. HCPC Recent Development

Table 177. Yunnan Baiyao Company Details

Table 178. Yunnan Baiyao Business Overview

Table 179. Yunnan Baiyao Vaginitis Drug Product

Table 180. Yunnan Baiyao Revenue (2020-2025) & (US$ Million)

Table 181. Yunnan Baiyao Recent Development

Table 182. Research Programs/Design for This Report

Table 183. Key Data Information from Secondary Sources

Table 184. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Vaginitis Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 2. Global Vaginitis Drug Market Share by Type: 2024 VS 2031

Figure 3. External Drug Features

Figure 4. Oral Drug Features

Figure 5. Global Vaginitis Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Global Vaginitis Drug Market Share by Application: 2024 VS 2031

Figure 7. Hospital Phamacy Case Studies

Figure 8. Retail Phamacy Case Studies

Figure 9. Online Case Studies

Figure 10. Vaginitis Drug Report Years Considered

Figure 11. Global Vaginitis Drug Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Vaginitis Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Vaginitis Drug Market Share by Region: 2024 VS 2031

Figure 14. Global Vaginitis Drug Market Share by Players in 2024

Figure 15. Global Top Vaginitis Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaginitis Drug as of 2024)

Figure 16. The Top 10 and 5 Players Market Share by Vaginitis Drug Revenue in 2024

Figure 17. North America Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America Vaginitis Drug Market Share by Type (2020-2031)

Figure 19. North America Vaginitis Drug Market Share by Application (2020-2031)

Figure 20. North America Vaginitis Drug Market Share by Country (2020-2031)

Figure 21. United States Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Vaginitis Drug Market Share by Type (2020-2031)

Figure 25. Europe Vaginitis Drug Market Share by Application (2020-2031)

Figure 26. Europe Vaginitis Drug Market Share by Country (2020-2031)

Figure 27. Germany Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. China Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. China Vaginitis Drug Market Share by Type (2020-2031)

Figure 35. China Vaginitis Drug Market Share by Application (2020-2031)

Figure 36. Asia Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Asia Vaginitis Drug Market Share by Type (2020-2031)

Figure 38. Asia Vaginitis Drug Market Share by Application (2020-2031)

Figure 39. Asia Vaginitis Drug Market Share by Region (2020-2031)

Figure 40. Japan Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. South Korea Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. China Taiwan Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Southeast Asia Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. India Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Australia Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East, Africa, and Latin America Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East, Africa, and Latin America Vaginitis Drug Market Share by Type (2020-2031)

Figure 48. Middle East, Africa, and Latin America Vaginitis Drug Market Share by Application (2020-2031)

Figure 49. Middle East, Africa, and Latin America Vaginitis Drug Market Share by Country (2020-2031)

Figure 50. Brazil Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Mexico Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Turkey Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Israel Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. GCC Countries Vaginitis Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. Pfizer Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 57. Bayer Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 58. Sanofi Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 59. Teva Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 60. Sandoz Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 61. Prestige Consumer Healthcare Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 62. Lupin Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 63. Bausch Health Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 64. Globela Pharma Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 65. Padagis Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 66. Galderma Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 67. Perrigo Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 68. Johnson & Johnson Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 69. Sinopharm Group Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 70. Tongfang Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 71. Lukang Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 72. Kelun Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 73. Shandong Shijiazhuang Pharmaceutical Group Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 74. Livzon Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 75. Wuhan Haite Biopharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 76. Dare Bioscience Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 77. Conba Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 78. Luoxin Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 79. Yuanda Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 80. CR-Double Crane Pharmaceuticals Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 81. HCPC Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 82. Yunnan Baiyao Revenue Growth Rate in Vaginitis Drug Business (2020-2025)

Figure 83. Bottom-up and Top-down Approaches for This Report

Figure 84. Data Triangulation

Figure 85. Key Executives Interviewed